scientists retooling bacteria to cure disease called phenylketonuria
Last Updated : GMT 09:07:40
Egypt Today, egypt today
Egypt Today, egypt today
Last Updated : GMT 09:07:40
Egypt Today, egypt today

Scientists retooling bacteria to cure disease called phenylketonuria

Egypt Today, egypt today

Egypt Today, egypt today Scientists retooling bacteria to cure disease called phenylketonuria

The blood of a two week-old infant is collected.
New York - Egypt Today

In a study carried out over the summer, a group of volunteers drank a white, peppermint-ish concoction laced with billions of bacteria. The microbes had been engineered to break down a naturally occurring toxin in the blood.

The vast majority of us can do this without any help. But for those who cannot, these microbes may someday become a living medicine.

The trial marks an important milestone in a promising scientific field known as synthetic biology. Two decades ago, researchers started to tinker with living things the way engineers tinker with electronics.

They took advantage of the fact that genes typically do not work in isolation. Instead, many genes work together, activating and deactivating one another. Synthetic biologists manipulated these communications, creating cells that respond to new signals or respond in new ways.

Until now, the biggest effect has been industrial. Companies are using engineered bacteria as miniature factories, assembling complex molecules like antibiotics or compounds used to make clothing.

In recent years, though, a number of research teams have turned their attention inward. They want to use synthetic biology to fashion microbes that enter our bodies and treat us from the inside.

The bacterial concoction that volunteers drank this summer — tested by the company Synlogic — may become the first synthetic biology-based medical treatment to gain approval by the US Food and Drug Administration.

The bacteria are designed to treat a rare inherited disease called phenylketonuria, or PKU. People with the condition must avoid dietary protein in foods such as meat and cheese, because their bodies cannot break down a byproduct, an amino acid called phenylalanine.

As phenylalanine builds up in the blood, it can damage neurons in the brain, leading to delayed development, intellectual disability and psychiatric disorders. The traditional treatment for PKU is a strict low-protein diet, accompanied by shakes loaded with nutritional supplements.

But in experiments on mice and monkeys, Synlogic’s bacteria showed promise as an alternative treatment. Earlier this month, company investigators announced positive results in a clinical trial with healthy volunteers.

The researchers are now going forward with a trial on people with PKU and expect to report initial results next year.

Tal Danino, a synthetic biologist at Columbia University, said that a number of other researchers are working on similar projects, but no one has moved forward as fast as Synlogic. “They’re leading the charge,” he said.

One of Synlogic’s co-founders, James Collins, a synthetic biologist at the Massachusetts Institute of Technology, published one of synthetic biology’s first proofs of principle in 2000.

He and his colleagues endowed E. coli bacteria with a way to turn a gene on and off when they were exposed to certain chemicals — “like a light switch for genes,” Collins said.

At first, the scientists envisioned using rewired bacteria as environmental sensors — perhaps detecting airborne biological weapons and producing a chemical signal in response.

But then came the microbiome. In the mid-2000s, microbiologists began charting our inner menagerie of microbes, the vast diversity of organisms that live inside healthy people. The microbiome is continually carrying out complex biochemistry, some of which helps shield us from diseases, scientists found.

Synthetic biologists soon began wondering whether they could add engineered bacteria to the mix — perhaps as internal sensors for signs of disease, or even as gut-based factories that make drugs the body needs.

“You can’t overestimate the impact of the microbiome work,” said Jeff Hasty, a former student of Collins who now runs his own lab at the University of California, San Diego. “That, in a nutshell, changed everything.”

Collins and Timothy Lu, another synthetic biologist at MIT, co-founded Synlogic in 2013, and the company began looking for diseases to take on. One of their picks was PKU, which affects 16,500 people in the United States.

Drugs have recently become available that can drive down levels of phenylalanine. But they only work in a fraction of patients, and they come with side effects of their own.
“The current tools that we have available are not good enough,” said Christine Brown, the executive director of the National PKU Alliance.
For years, researchers have explored treating PKU with gene therapy, hoping to insert working versions of the defective gene, called PAH, into a patient’s own cells. But the approach has not moved beyond studies in mice.

To Synlogic, PKU looked like a ripe opportunity to use synthetic biology to create a treatment that might gain government approval.
Company researchers selected a harmless strain of E. coli that has been studied for more than a century. “Most people have healthy, good E. coli in their intestinal tracts,” said Paul Miller, the chief scientific officer of Synlogic.

The researchers inserted genes into the bacteria’s DNA so that once they arrived in the gut, they could break down phenylalanine like our own cells do.
One of the new genes encodes a pump that the bacteria use to suck up phenylalanine around them. A second gene encodes an enzyme that breaks down the phenylalanine into fragments. The bacteria then release the fragments, which get washed out in urine.

The Synlogic team wanted the microbes to break down phenylalanine only in the right place and at the right time in the human body. So they engineered the bacteria to keep their phenylalanine genes shut down if they sensed high levels of oxygen around them.

Only when they arrived in a place with little oxygen — the gut — did they turn on their engineered genes.

To test the bacteria, the researchers created mice with the mutation that causes PKU. When the mice received a dose of the bacteria, the phenylalanine in their blood dropped by 38 per cent, compared with mice without the microbes.

The researchers also tried out the bacteria on healthy monkeys. When monkeys without the microbes ate a high-protein diet, they experienced a spike of phenylalanine in their blood. The monkeys with engineered bacteria in their guts experienced only a gentle bump.

For their human trial, Synlogic recruited healthy people to swallow the bacteria. Some took a single dose, while others drank increasingly large ones over the course of a week. After ingesting the bacteria, the volunteers drank a shake or ate solid food high in protein.

Recently, Synlogic announced that the trial had demonstrated people could safely tolerate the bacteria. In addition, the more bacteria they ingested, the more bits of phenylalanine wound up in their urine — a sign the bacteria were doing their job.

The next step will be to see if the microbes can lower phenylalanine levels in people with PKU.

“I’m amazed at how fast we got to where we are,” said Collins, who was not involved in Synlogic’s PKU research.

egypttoday
egypttoday

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

scientists retooling bacteria to cure disease called phenylketonuria scientists retooling bacteria to cure disease called phenylketonuria



GMT 05:49 2012 Monday ,02 April

South Sudan peace talks fragile

GMT 15:03 2013 Saturday ,28 September

\'The Amazing Tastes of Thailand Fest 2013\'

GMT 13:43 2017 Wednesday ,01 February

MADA- 10 Years of Hard Work and Impact

GMT 20:27 2017 Wednesday ,15 March

Science unravels spiders' monstrous food web

GMT 08:46 2014 Tuesday ,28 January

Latifah to sing \'America the Beautiful\'

GMT 21:52 2012 Tuesday ,07 August

Ernesto growls at Yucatan

GMT 22:54 2016 Thursday ,29 September

Rosetta: beginning of the end for Europe's comet craft

GMT 20:28 2017 Sunday ,30 April

Bourse loses EGP 8 bn in morning trading

GMT 07:56 2017 Wednesday ,15 March

Moscow apparently has forces at base in Egypt

GMT 21:25 2017 Thursday ,20 April

Sisi receives US defence secretary

GMT 20:58 2016 Tuesday ,18 October

Prime Minister of Kuwait meets FANA Delegates

GMT 11:38 2011 Wednesday ,15 June

Not guilty plea in blood diamond trial

GMT 07:33 2017 Monday ,13 February

Leading English Premier League scorers

GMT 11:35 2017 Sunday ,05 November

Tamkeen Chief Executive Bahrain to host GEW2017

GMT 08:39 2017 Thursday ,07 September

Kurdish Peshmerga is ready with plan to liberate Hawija

GMT 15:44 2012 Sunday ,29 April

Sauerkraut salad

GMT 10:00 2018 Tuesday ,16 January

No Brexit deal would cost Scotland £12.7bn

GMT 08:44 2013 Saturday ,23 February

Mexican Facebook page threatened over crime posts

GMT 07:17 2011 Friday ,29 July

Japan PM to unveil plan to reduce nuclear power

GMT 23:23 2016 Monday ,21 March

Gender bending in watches: a wristy business
 
 Egypt Today Facebook,egypt today facebook  Egypt Today Twitter,egypt today twitter Egypt Today Rss,egypt today rss  Egypt Today Youtube,egypt today youtube  Egypt Today Youtube,egypt today youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©

egypttoday egypttoday egypttoday egypttoday
egypttoday egypttoday egypttoday
egypttoday
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
egypttoday, Egypttoday, Egypttoday